Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The mutant KRAS peptide-HLA class I complex is a tumor-specific neoantigen presented on the surface of cancer cells. It is formed when intracellular mutant Kirsten rat sarcoma viral oncogene homolog (KRAS) proteins (such as those harboring G12D, G12V, or G12C mutations) are degraded by the proteasome, and the resulting mutant peptide fragments are loaded onto human leukocyte antigen (HLA) class I molecules for presentation to the immune system. Because KRAS mutations are highly prevalent driver oncogenes in solid tumors—particularly pancreatic, colorectal, and non-small cell lung cancers—but are notoriously difficult to target directly with small molecules, this cell-surface complex represents an attractive target for immunotherapy.
Therapeutic strategies targeting this complex include T-cell receptor-engineered T-cell (TCR-T) therapies, chimeric antigen receptor T-cell (CAR-T) therapies, and T-cell receptor mimic (TCRm) bispecific antibodies or antibody-drug conjugates. These agents, such as AFNT-211 and NW-301V, are designed to specifically recognize the mutant peptide in the context of a specific HLA allele (e.g., HLA-A*11:01 or HLA-A*02:01) without cross-reacting with wild-type KRAS. Clinical challenges include the requirement for patient HLA-matching, potential on-target off-tumor toxicities due to cross-reactivity with self-peptides, and tumor resistance mechanisms such as HLA downregulation or loss.
T-cell receptor-engineered T-cell (TCR-T) therapy, chimeric antigen receptor T-cell (CAR-T) therapy, T-cell receptor mimic (TCRm) bispecific antibody, and T-cell receptor mimic antibody-drug conjugate (TCRm-ADC)
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mutant Kirsten rat sarcoma viral oncogene homolog peptide-human leukocyte antigen class I complex (mKRAS-HLA-I).